Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir - ViiV Healthcare

Next Previous
X
Search
Drug Profile

Dolutegravir - ViiV Healthcare

Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay; Tivicay PD

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi-GlaxoSmithKline Pharmaceuticals
  • Developer Bellvitge University Hospital; GSK; INSERM; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); PENTA Foundation; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; Viatris; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 19 Jun 2024 National Institute of Allergy and Infectious Diseases (NIAID) initiates a phase I/II trial in HIV-1 infections (In infants, In children, In adolescents, Treatment-experienced, Treatment-naive, Combination therapy) in Kenya (PO, Granules for suspension) in April 2011 (NCT01302847) (EudraCT2010-020988-20)
  • 18 Oct 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase I/II trial in HIV-1 infections (In infants, In children, In adolescents, Treatment-experienced, Treatment-naive, Combination therapy) in USA, Botswana, Brazil, Kenya, South Africa, Tanzania, Thailand and Zimbabwe (PO, Granules for suspension) (NCT01302847) (EudraCT2010-020988-20)
  • 05 Oct 2022 Phase-I clinical trials in HIV-1 infections (In infants, In neonates, Prevention) in USA (PO) (NCT05406583)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top